M42, the global health powerhouse, has entered into a groundbreaking agreement with AstraZeneca, a global leader in science-led biopharmaceuticals, in order to advance preventive healthcare and next-generation precision medicine.
As AstraZeneca’s clinical genomics partner of choice in the Middle East region, M42 will conduct sequencing of hereditary breast cancer genes. This intends to develop personalized care and prevention strategies tailored to the specific needs of each patient.
The initiative demonstrates M42’s advanced multi-omics sequencing capabilities in the realm of oncological diagnostics, a relatively new field that has tremendous potential to improve patient outcomes amid the growing global cancer burden.
Dr. Fahed Al Marzooqi, Deputy Group Chief Operating Officer at M42, said that, “M42 operates at the cutting edge of innovation and is committed to reshaping the future of health with its provision of next-generation preventive and precision medicine. This pioneering program, powered by disruptive omics technologies, aims to enable personalized cancer treatment and intervention, contributing directly to patient outcomes and paving the way for preventive medicine, in keeping with our mission to support people, not just patients and prevention, not just treatment. Our partnership with AstraZeneca aims to further lay the groundwork for a future in which precision medicine is the norm for effectively combatting health challenges.”
“This collaboration with M42 represents a significant step forward in our commitment to advancing personalized precision medicine in cancer research. At AstraZeneca, we are happy to be pioneering efforts in preventative cancer care by utilizing M42’s state-of-the-art genomics expertise. It is our priority to continue striving to enhance patient outcomes for the health of people, society, and the planet,” commented Peter Raouf, GCC Oncology Business Unit Director at AstraZeneca.
By facilitating the sequencing of cancer genes, M42 will help determine each patient’s genetic risk for cancer, thus ensuring that preventive measures can be explored before cancer develops, or at an early stage.
According to the statement, “In doing so, the health-tech leader, in partnership with AstraZeneca, is also providing one of the first companion diagnostics programs in the Gulf, with findings that could be utilized to optimize personalized drug-based interventions for patients.”
